<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04752163</url>
  </required_header>
  <id_info>
    <org_study_id>2020-0946</org_study_id>
    <secondary_id>NCI-2021-00603</secondary_id>
    <secondary_id>2020-0946</secondary_id>
    <nct_id>NCT04752163</nct_id>
  </id_info>
  <brief_title>DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia</brief_title>
  <official_title>An Open-Label Phase 1/2 Multi-Arm Study of DS-1594b as a Single-Agent and in Combination With Azacitidine and Venetoclax or Mini-HCVD for the Treatment of Patients With Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I/II trial studies the effect of DS-1594b with or without azacitidine, venetoclax,&#xD;
      or mini-HCVD in treating patients with acute myeloid leukemia or acute lymphoblastic leukemia&#xD;
      that has come back (recurrent) or not responded to treatment (refractory). Chemotherapy&#xD;
      drugs, such as azacitidine, venetoclax, and mini-HCVD, work in different ways to stop the&#xD;
      growth of cancer cells, either by killing the cells, by stopping them from dividing, or by&#xD;
      stopping them from spreading. DS-1594b may inhibit specific protein bindings that cause blood&#xD;
      cancer. Giving DS-1594b, azacitidine, and venetoclax, or mini-HCVD may work better in&#xD;
      treating patients with acute myeloid leukemia or acute lymphoblastic leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OUTLINE: This is a phase I, dose-escalation study of DS-1594b followed by a phase II study.&#xD;
&#xD;
      PHASE I: Patients receive DS-1594b orally (PO) twice daily (BID) on days 1-28 in the absence&#xD;
      of disease progression or unacceptable toxicity.&#xD;
&#xD;
      DRUG-DRUG INTERACTION SUB-STUDY: Patients receive DS-1594b PO BID on days 1-8 and 19-28, and&#xD;
      posaconazole PO BID on day 9 and once daily (QD) on days 10-18 or voriconazole PO BID on days&#xD;
      9-18 in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      FOOD-EFFECT SUB STUDY: Patients receive DS-1594b PO BID on days 1-8 within 30 minutes after&#xD;
      eating a standard meal and PO BID on days 9-15 under fasting conditions in the absence of&#xD;
      disease progression or unacceptable toxicity.&#xD;
&#xD;
      PHASE II: Patients are assigned to 1 of 4 cohorts.&#xD;
&#xD;
      COHORT A: Patients with MLLr receive DS-1594b PO BID on days 1-28. Cycles repeat every 28&#xD;
      days for up to 2 years in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      COHORT B: Patients with NPM1m receive DS-1594b PO BID on days 1-28. Cycles repeat every 28&#xD;
      days for up to 2 years in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      COHORT C: Patients receive DS-1594b PO BID on days 1-28, venetoclax PO QD on days 1-28, and&#xD;
      azacitidine intravenously (IV) or subcutaneously (SC) on days 1-7. Cycles repeat every 28&#xD;
      days for up to 2 years in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      COHORT D: Patients receive DS-1594b PO BID on days 1-28. For cycles 1, 3, 5, 7, patients also&#xD;
      receive cyclophosphamide IV over 3 hours on days 1-3, mesna IV over 24 hours on days 1-3,&#xD;
      vincristine IV on days 1 and 11, dexamethasone PO or IV on days 1-4 and 11-14, filgrastim SC&#xD;
      on days 1-28, methotrexate intrathecally (IT) on day 2 of cycles 1 and 3, and cytarabine IT&#xD;
      on day 7 of cycles 1 and 3. For cycles 2, 4, 6, 8, patients also receive methotrexate IV over&#xD;
      24 hours on day 1, cytarabine BID IV over 3 hours on days 2 and 3, leucovorin IV or PO every&#xD;
      6 hours (Q6H) starting 12 hours after completion of methotrexate, filgrastim SC days 1-28,&#xD;
      cytarabine IT on day 5-8 of cycles 2 and 4 and methotrexate IT on days 8-11 of cycles 2 and&#xD;
      4. Patients with CD20 expression may also receive rituximab IV on days 1 and 11 of cycles 1&#xD;
      and 3 and days 1 and 8 of cycles 2 and 4. Cycles repeat every 28 days for up to 8 cycles in&#xD;
      the absence of disease progression or unacceptable toxicity. Patients may then receive&#xD;
      DS-1594b PO BID on days 1-28, vincristine IV over 15 minutes on day 7 and prednisone PO BID&#xD;
      on days 1-5. Cycles repeat every 28 days for up to 2 years in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up at days 30 and 100.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 25, 2021</start_date>
  <completion_date type="Anticipated">November 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) (Phase I)</measure>
    <time_frame>Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended phase 2 dose (RP2D) (Phase I)</measure>
    <time_frame>Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse events (Phase I)</measure>
    <time_frame>up to 30 days after discontinuation of study medication</time_frame>
    <description>Measured by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Complete remission (CR) and complete remission with partial hematologic recover (CRh) rate with DS-1594b monotherapy in recurrent/refractory (R/R) acute myeloid leukemia (AML) with mixed-lineage leukemia rearrangement (MLLr) (Phase II, Cohort A)</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CR/CRh rate with DS-1594b monotherapy in R/R AML with nucleophosmin 1 mutation (NPM1m) (Phase II, Cohort B)</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CR+CRh rate of DS1594b in combination with azacitidine and venetoclax in R/R MLLr or R/R NPM1m AML (Phase II, Cohort C)</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CR+CRh rate of DS1594b in combination with mini-HCVD in R/R ALL with MLLr (Phase II, Cohort D)</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CR+ complete remission with incomplete hematologic recovery (CRi) rate of DS-1594b in combination with mini-HCVD in R/R ALL with MLLr</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite CR (CRc) rate</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Defined as CR + complete remission with incomplete blood count recovery (CRi), morphologic leukemia free survival (MLFS), partial remission (PR), and overall response rate of subjects with R/R AML and R/R ALL treated on single-agent or combinations of DS-1594b.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MLFS rate</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PR rate</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Defined as CR + CRi + MLFS + PR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Estimated using the Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first response and time to best response</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Estimated using the Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of durable transfusion independence (TI)</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival</measure>
    <time_frame>up to 1 year, 4 months</time_frame>
    <description>Estimated using the Kaplan-Meier method. From the date of start treatment to the date of disease relapse or date of death whichever occurs first, or to the date of last follow-up for patients who are alive and have no relapsed disease at the time of data collection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>up to 1 year, 4 months</time_frame>
    <description>Estimated using the Kaplan-Meier method.From the date of the treatment start to the date of death or to the date of last follow-up if patients are alive at the time of data collection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality rate</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality rate</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects able to proceed to hematopoietic stem cell transplantation (HSCT) without additional AML therapy</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median duration to HSCT from the initiation of single-agent or combinations of DS-1594b in subjects with RR AML and R/R ALL</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">122</enrollment>
  <condition>Hematopoietic and Lymphoid Cell Neoplasm</condition>
  <condition>Recurrent Acute Lymphoblastic Leukemia</condition>
  <condition>Recurrent Acute Myeloid Leukemia</condition>
  <condition>Recurrent Chronic Myelomonocytic Leukemia</condition>
  <condition>Recurrent Myelodysplastic Syndrome</condition>
  <condition>Refractory Acute Lymphoblastic Leukemia</condition>
  <condition>Refractory Acute Myeloid Leukemia</condition>
  <condition>Refractory Chronic Myelomonocytic Leukemia</condition>
  <condition>Refractory Myelodysplastic Syndrome</condition>
  <arm_group>
    <arm_group_label>Cohort A and B (DS-1594b)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with MLLr or NPM1m receive DS-1594b PO BID on days 1-28. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C (DS-1594b, venetoclax, azacitidine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive DS-1594b PO BID on days 1-28, venetoclax PO QD on days 1-28, and azacitidine IV or SC on days 1-7. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort D (DS-1594b, mini-HCVD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive DS-1594b PO BID on days 1-28. For additional information, see trial description.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug-Drug Interaction (DS-1594b, posaconazole, voriconazole)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive DS-1594b PO BID on days 1-8 and 19-28, and posaconazole PO BID on day 9 and QD on days 10-18 or voriconazole PO BID on days 9-18 in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Food-Effect (DS-1594b)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive DS-1594b PO BID on days 1-8 within 30 minutes after eating a standard meal and PO BID on days 9-15 under fasting conditions in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase I (DS-1594b)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive DS-1594b PO BID on days 1-28 in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DS-1594b</intervention_name>
    <description>Given DS-1594b PO</description>
    <arm_group_label>Cohort A and B (DS-1594b)</arm_group_label>
    <arm_group_label>Cohort C (DS-1594b, venetoclax, azacitidine)</arm_group_label>
    <arm_group_label>Cohort D (DS-1594b, mini-HCVD)</arm_group_label>
    <arm_group_label>Drug-Drug Interaction (DS-1594b, posaconazole, voriconazole)</arm_group_label>
    <arm_group_label>Food-Effect (DS-1594b)</arm_group_label>
    <arm_group_label>Phase I (DS-1594b)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacitidine</intervention_name>
    <description>Given IV or SC</description>
    <arm_group_label>Cohort C (DS-1594b, venetoclax, azacitidine)</arm_group_label>
    <other_name>5 AZC</other_name>
    <other_name>5-AC</other_name>
    <other_name>5-Azacytidine</other_name>
    <other_name>5-AZC</other_name>
    <other_name>Azacytidine</other_name>
    <other_name>Azacytidine, 5-</other_name>
    <other_name>Ladakamycin</other_name>
    <other_name>Mylosar</other_name>
    <other_name>Onureg</other_name>
    <other_name>U-18496</other_name>
    <other_name>Vidaza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Cohort D (DS-1594b, mini-HCVD)</arm_group_label>
    <other_name>(-)-Cyclophosphamide</other_name>
    <other_name>2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate</other_name>
    <other_name>Carloxan</other_name>
    <other_name>Ciclofosfamida</other_name>
    <other_name>Ciclofosfamide</other_name>
    <other_name>Cicloxal</other_name>
    <other_name>Clafen</other_name>
    <other_name>Claphene</other_name>
    <other_name>CP monohydrate</other_name>
    <other_name>CTX</other_name>
    <other_name>CYCLO-cell</other_name>
    <other_name>Cycloblastin</other_name>
    <other_name>Cycloblastine</other_name>
    <other_name>Cyclophospham</other_name>
    <other_name>Cyclophosphamid monohydrate</other_name>
    <other_name>Cyclophosphamide Monohydrate</other_name>
    <other_name>Cyclophosphamidum</other_name>
    <other_name>Cyclophosphan</other_name>
    <other_name>Cyclophosphane</other_name>
    <other_name>Cyclophosphanum</other_name>
    <other_name>Cyclostin</other_name>
    <other_name>Cyclostine</other_name>
    <other_name>Cytophosphan</other_name>
    <other_name>Cytophosphane</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Fosfaseron</other_name>
    <other_name>Genoxal</other_name>
    <other_name>Genuxal</other_name>
    <other_name>Ledoxina</other_name>
    <other_name>Mitoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Revimmune</other_name>
    <other_name>Syklofosfamid</other_name>
    <other_name>WR- 138719</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Given IT</description>
    <arm_group_label>Cohort D (DS-1594b, mini-HCVD)</arm_group_label>
    <other_name>.beta.-Cytosine arabinoside</other_name>
    <other_name>1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone</other_name>
    <other_name>1-.beta.-D-Arabinofuranosylcytosine</other_name>
    <other_name>1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone</other_name>
    <other_name>1-Beta-D-arabinofuranosylcytosine</other_name>
    <other_name>1.beta.-D-Arabinofuranosylcytosine</other_name>
    <other_name>2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-</other_name>
    <other_name>2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-</other_name>
    <other_name>Alexan</other_name>
    <other_name>Ara-C</other_name>
    <other_name>ARA-cell</other_name>
    <other_name>Arabine</other_name>
    <other_name>Arabinofuranosylcytosine</other_name>
    <other_name>Arabinosylcytosine</other_name>
    <other_name>Aracytidine</other_name>
    <other_name>Aracytin</other_name>
    <other_name>Aracytine</other_name>
    <other_name>Beta-Cytosine Arabinoside</other_name>
    <other_name>CHX-3311</other_name>
    <other_name>Cytarabinum</other_name>
    <other_name>Cytarbel</other_name>
    <other_name>Cytosar</other_name>
    <other_name>Cytosine Arabinoside</other_name>
    <other_name>Cytosine-.beta.-arabinoside</other_name>
    <other_name>Cytosine-beta-arabinoside</other_name>
    <other_name>Erpalfa</other_name>
    <other_name>Starasid</other_name>
    <other_name>Tarabine PFS</other_name>
    <other_name>U 19920</other_name>
    <other_name>U-19920</other_name>
    <other_name>Udicil</other_name>
    <other_name>WR-28453</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Given PO or IV</description>
    <arm_group_label>Cohort D (DS-1594b, mini-HCVD)</arm_group_label>
    <other_name>Aacidexam</other_name>
    <other_name>Adexone</other_name>
    <other_name>Aknichthol Dexa</other_name>
    <other_name>Alba-Dex</other_name>
    <other_name>Alin</other_name>
    <other_name>Alin Depot</other_name>
    <other_name>Alin Oftalmico</other_name>
    <other_name>Amplidermis</other_name>
    <other_name>Anemul mono</other_name>
    <other_name>Auricularum</other_name>
    <other_name>Auxiloson</other_name>
    <other_name>Baycadron</other_name>
    <other_name>Baycuten</other_name>
    <other_name>Baycuten N</other_name>
    <other_name>Cortidexason</other_name>
    <other_name>Cortisumman</other_name>
    <other_name>Decacort</other_name>
    <other_name>Decadrol</other_name>
    <other_name>Decadron</other_name>
    <other_name>Decadron DP</other_name>
    <other_name>Decalix</other_name>
    <other_name>Decameth</other_name>
    <other_name>Decasone R.p.</other_name>
    <other_name>Dectancyl</other_name>
    <other_name>Dekacort</other_name>
    <other_name>Deltafluorene</other_name>
    <other_name>Deronil</other_name>
    <other_name>Desamethasone</other_name>
    <other_name>Desameton</other_name>
    <other_name>Dexa-Mamallet</other_name>
    <other_name>Dexa-Rhinosan</other_name>
    <other_name>Dexa-Scheroson</other_name>
    <other_name>Dexa-sine</other_name>
    <other_name>Dexacortal</other_name>
    <other_name>Dexacortin</other_name>
    <other_name>Dexafarma</other_name>
    <other_name>Dexafluorene</other_name>
    <other_name>Dexalocal</other_name>
    <other_name>Dexamecortin</other_name>
    <other_name>Dexameth</other_name>
    <other_name>Dexamethasone Intensol</other_name>
    <other_name>Dexamethasonum</other_name>
    <other_name>Dexamonozon</other_name>
    <other_name>Dexapos</other_name>
    <other_name>Dexinoral</other_name>
    <other_name>Dexone</other_name>
    <other_name>Dinormon</other_name>
    <other_name>Fluorodelta</other_name>
    <other_name>Fortecortin</other_name>
    <other_name>Gammacorten</other_name>
    <other_name>Hexadecadrol</other_name>
    <other_name>Hexadrol</other_name>
    <other_name>Lokalison-F</other_name>
    <other_name>Loverine</other_name>
    <other_name>Methylfluorprednisolone</other_name>
    <other_name>Millicorten</other_name>
    <other_name>Mymethasone</other_name>
    <other_name>Orgadrone</other_name>
    <other_name>Spersadex</other_name>
    <other_name>TaperDex</other_name>
    <other_name>Visumetazone</other_name>
    <other_name>ZoDex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Filgrastim</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Cohort D (DS-1594b, mini-HCVD)</arm_group_label>
    <other_name>G-CSF</other_name>
    <other_name>Neupogen</other_name>
    <other_name>r-metHuG-CSF</other_name>
    <other_name>Recombinant Methionyl Human Granulocyte Colony Stimulating Factor</other_name>
    <other_name>rG-CSF</other_name>
    <other_name>Tevagrastim</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin</intervention_name>
    <description>Given IV or PO</description>
    <arm_group_label>Cohort D (DS-1594b, mini-HCVD)</arm_group_label>
    <other_name>Folinic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mesna</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Cohort D (DS-1594b, mini-HCVD)</arm_group_label>
    <other_name>2-Mercaptoethanesulfonate, Sodium Salt</other_name>
    <other_name>Ausobronc</other_name>
    <other_name>D-7093</other_name>
    <other_name>Filesna</other_name>
    <other_name>Mercaptoethane Sulfonate</other_name>
    <other_name>Mercaptoethanesulfonate</other_name>
    <other_name>Mesnex</other_name>
    <other_name>Mesnil</other_name>
    <other_name>Mesnum</other_name>
    <other_name>Mexan</other_name>
    <other_name>Mistabron</other_name>
    <other_name>Mistabronco</other_name>
    <other_name>Mitexan</other_name>
    <other_name>Mucofluid</other_name>
    <other_name>Mucolene</other_name>
    <other_name>UCB 3983</other_name>
    <other_name>Uromitexan</other_name>
    <other_name>Ziken</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Given IT</description>
    <arm_group_label>Cohort D (DS-1594b, mini-HCVD)</arm_group_label>
    <other_name>Abitrexate</other_name>
    <other_name>Alpha-Methopterin</other_name>
    <other_name>Amethopterin</other_name>
    <other_name>Brimexate</other_name>
    <other_name>CL 14377</other_name>
    <other_name>CL-14377</other_name>
    <other_name>Emtexate</other_name>
    <other_name>Emthexat</other_name>
    <other_name>Emthexate</other_name>
    <other_name>Farmitrexat</other_name>
    <other_name>Fauldexato</other_name>
    <other_name>Folex</other_name>
    <other_name>Folex PFS</other_name>
    <other_name>Lantarel</other_name>
    <other_name>Ledertrexate</other_name>
    <other_name>Lumexon</other_name>
    <other_name>Maxtrex</other_name>
    <other_name>Medsatrexate</other_name>
    <other_name>Metex</other_name>
    <other_name>Methoblastin</other_name>
    <other_name>Methotrexate LPF</other_name>
    <other_name>Methotrexate Methylaminopterin</other_name>
    <other_name>Methotrexatum</other_name>
    <other_name>Metotrexato</other_name>
    <other_name>Metrotex</other_name>
    <other_name>Mexate</other_name>
    <other_name>Mexate-AQ</other_name>
    <other_name>MTX</other_name>
    <other_name>Novatrex</other_name>
    <other_name>Rheumatrex</other_name>
    <other_name>Texate</other_name>
    <other_name>Tremetex</other_name>
    <other_name>Trexeron</other_name>
    <other_name>Trixilem</other_name>
    <other_name>WR-19039</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Posaconazole</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Drug-Drug Interaction (DS-1594b, posaconazole, voriconazole)</arm_group_label>
    <other_name>Noxafil</other_name>
    <other_name>SCH 56592</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Cohort D (DS-1594b, mini-HCVD)</arm_group_label>
    <other_name>.delta.1-Cortisone</other_name>
    <other_name>1, 2-Dehydrocortisone</other_name>
    <other_name>Adasone</other_name>
    <other_name>Cortancyl</other_name>
    <other_name>Dacortin</other_name>
    <other_name>DeCortin</other_name>
    <other_name>Decortisyl</other_name>
    <other_name>Decorton</other_name>
    <other_name>Delta 1-Cortisone</other_name>
    <other_name>Delta-Dome</other_name>
    <other_name>Deltacortene</other_name>
    <other_name>Deltacortisone</other_name>
    <other_name>Deltadehydrocortisone</other_name>
    <other_name>Deltasone</other_name>
    <other_name>Deltison</other_name>
    <other_name>Deltra</other_name>
    <other_name>Econosone</other_name>
    <other_name>Lisacort</other_name>
    <other_name>Meprosona-F</other_name>
    <other_name>Metacortandracin</other_name>
    <other_name>Meticorten</other_name>
    <other_name>Ofisolona</other_name>
    <other_name>Orasone</other_name>
    <other_name>Panafcort</other_name>
    <other_name>Panasol-S</other_name>
    <other_name>Paracort</other_name>
    <other_name>Perrigo Prednisone</other_name>
    <other_name>PRED</other_name>
    <other_name>Predicor</other_name>
    <other_name>Predicorten</other_name>
    <other_name>Prednicen-M</other_name>
    <other_name>Prednicort</other_name>
    <other_name>Prednidib</other_name>
    <other_name>Prednilonga</other_name>
    <other_name>Predniment</other_name>
    <other_name>Prednisone Intensol</other_name>
    <other_name>Prednisonum</other_name>
    <other_name>Prednitone</other_name>
    <other_name>Promifen</other_name>
    <other_name>Rayos</other_name>
    <other_name>Servisone</other_name>
    <other_name>SK-Prednisone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Cohort D (DS-1594b, mini-HCVD)</arm_group_label>
    <other_name>ABP 798</other_name>
    <other_name>BI 695500</other_name>
    <other_name>C2B8 Monoclonal Antibody</other_name>
    <other_name>Chimeric Anti-CD20 Antibody</other_name>
    <other_name>CT-P10</other_name>
    <other_name>IDEC-102</other_name>
    <other_name>IDEC-C2B8</other_name>
    <other_name>IDEC-C2B8 Monoclonal Antibody</other_name>
    <other_name>MabThera</other_name>
    <other_name>Monoclonal Antibody IDEC-C2B8</other_name>
    <other_name>PF-05280586</other_name>
    <other_name>Rituxan</other_name>
    <other_name>Rituximab ABBS</other_name>
    <other_name>Rituximab Biosimilar ABP 798</other_name>
    <other_name>Rituximab Biosimilar BI 695500</other_name>
    <other_name>Rituximab Biosimilar CT-P10</other_name>
    <other_name>Rituximab Biosimilar GB241</other_name>
    <other_name>Rituximab Biosimilar IBI301</other_name>
    <other_name>Rituximab Biosimilar JHL1101</other_name>
    <other_name>Rituximab Biosimilar PF-05280586</other_name>
    <other_name>Rituximab Biosimilar RTXM83</other_name>
    <other_name>Rituximab Biosimilar SAIT101</other_name>
    <other_name>rituximab biosimilar TQB2303</other_name>
    <other_name>rituximab-abbs</other_name>
    <other_name>RTXM83</other_name>
    <other_name>Truxima</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venetoclax</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Cohort C (DS-1594b, venetoclax, azacitidine)</arm_group_label>
    <other_name>ABT-0199</other_name>
    <other_name>ABT-199</other_name>
    <other_name>ABT199</other_name>
    <other_name>GDC-0199</other_name>
    <other_name>RG7601</other_name>
    <other_name>Venclexta</other_name>
    <other_name>Venclyxto</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Cohort D (DS-1594b, mini-HCVD)</arm_group_label>
    <other_name>Leurocristine</other_name>
    <other_name>VCR</other_name>
    <other_name>Vincrystine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Voriconazole</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Drug-Drug Interaction (DS-1594b, posaconazole, voriconazole)</arm_group_label>
    <other_name>Vfend</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provision of written (signed) informed consent form (ICF) by the subject or legal&#xD;
             guardian prior to the performance of any study-specific procedures, according to&#xD;
             International Council on Harmonisation (ICH) and local regulatory requirements.&#xD;
             Subject must be fully informed about their illness and the investigational nature of&#xD;
             the study protocol (including foreseeable risks and possible toxicities) and must sign&#xD;
             and date an Institutional Review Board (IRB)/Independent Ethics Committee (IEC)&#xD;
             approved informed consent form (ICF)(including Health Insurance Portability and&#xD;
             Accountability Act authorization [HIPAA], if applicable) before performance of any&#xD;
             study-specific procedures or examinations&#xD;
&#xD;
          -  Subjects must be willing and able to comply with the protocol&#xD;
&#xD;
          -  Subjects with AML or ALL, diagnosed according to the 2016 criteria by the World Health&#xD;
             Organization (WHO) who are refractory or relapsed (any salvage) with no available&#xD;
             therapies or not candidates for available therapies. For subjects with prior MDS or&#xD;
             chronic myelomonocytic leukemia (CMML) or MPN who transformed to AML, therapy received&#xD;
             for MDS, CMML, or MPN is NOT considered as prior therapy for AML except for MDS or&#xD;
             CMML treated with HMAs. Subjects with MDS or CMML treated with HMA therapies who&#xD;
             progress to AML and have no available therapies or are not candidates for available&#xD;
             therapies, will be eligible at the time of progression to AML. In Phase 1: all R/R AML&#xD;
             or R/R ALL subjects irrespective of mutations will be eligible. In Phase 2 Cohort A&#xD;
             only R/R AML with MLLr will be eligible. In Phase 2 Cohort B only R/R AML with NPM1m&#xD;
             will be eligible. In Phase 2 Cohorts C and D: Only R/R AML or R/R ALL subjects with an&#xD;
             MLLr or NPM1m will be eligible&#xD;
&#xD;
          -  Prior therapy with hydroxyurea, chemotherapy, biological or targeted therapy (e.g.&#xD;
             FLT3 inhibitors, other kinase inhibitors), or hematopoietic growth factors is&#xD;
             permitted&#xD;
&#xD;
          -  Age 18 years or older&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2&#xD;
&#xD;
          -  Total bilirubin =&lt; 1.5 times upper limit of normal (x ULN)&#xD;
&#xD;
          -  Aspartate aminotransferase or alanine aminotransferase =&lt; 2.5 x ULN (aspartate&#xD;
             aminotransferase or alanine aminotransferase =&lt; 5.0 x ULN if deemed related to&#xD;
             leukemia by the treating physician)&#xD;
&#xD;
          -  Creatinine clearance &gt;= 50 mL/min as calculated using the modified Cockcroft-Gault&#xD;
             equation&#xD;
&#xD;
          -  Serum electrolytes within the institution's normal limits: potassium, calcium (total&#xD;
             calcium, calcium corrected for serum albumin in case of hypoalbuminemia or ionized&#xD;
             calcium) and magnesium. If outside of the institution's normal range, subject will be&#xD;
             eligible when electrolytes are corrected&#xD;
&#xD;
          -  In the absence of rapidly progressive disease, the interval from prior treatment to&#xD;
             the time of initiation of protocol therapy will be at least 14 days for prior&#xD;
             anti-leukemic therapy with the exception of hydroxyurea as noted below OR at least 5&#xD;
             half-lives for cytotoxic/noncytotoxic agents, whichever is shorter. The half-life for&#xD;
             the therapy in question will be based on published pharmacokinetic literature&#xD;
             (abstracts, manuscripts, investigator brochure's, or drug-administration manuals) and&#xD;
             will be documented in the protocol eligibility document. Since the effect of therapy&#xD;
             may be delayed, use of hydroxyurea for subjects with rapidly proliferative disease is&#xD;
             allowed before the start of study therapy and on study and hydroxyurea will not&#xD;
             require a washout&#xD;
&#xD;
          -  Concurrent therapy for central nervous system (CNS) prophylaxis or continuation of&#xD;
             therapy for controlled CNS disease is permitted. Subjects with a known history of CNS&#xD;
             disease or leukemic brain metastasis must have been treated locally, have at least 3&#xD;
             consecutive lumbar punctures (LPs) with no evidence of CNS leukemia, and must be&#xD;
             clinically stable for at least 4 weeks prior to enrollment and have no ongoing&#xD;
             neurological symptoms that in the opinion of the treating physician are related to the&#xD;
             CNS disease (sequelae that are a consequence of the treatment of the CNS disease are&#xD;
             acceptable)&#xD;
&#xD;
          -  Females must be surgically or biologically sterile or postmenopausal (amenorrheic for&#xD;
             at least 12 months) or if of childbearing potential, must have a negative serum or&#xD;
             urine pregnancy test within 72 hours before the start of the treatment&#xD;
&#xD;
          -  Women of childbearing potential must agree to use an adequate method of contraception&#xD;
             during the study and until 4 months after the last treatment. Males must be surgically&#xD;
             or biologically sterile or agree to use an adequate method of contraception during the&#xD;
             study until 3 months after the last treatment. Adequate methods of contraception&#xD;
             include:&#xD;
&#xD;
               -  Total abstinence when this is in line with the preferred and usual lifestyle of&#xD;
                  the subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal,&#xD;
                  postovulation methods) and withdrawal are not acceptable methods of&#xD;
                  contraception.&#xD;
&#xD;
               -  Female sterilization (have had surgical bilateral oophorectomy with or without&#xD;
                  hysterectomy) or tubal ligation at least six weeks before taking study treatment.&#xD;
                  In case of oophorectomy alone, only when the reproductive status of the woman has&#xD;
                  been confirmed by follow up hormone level assessment&#xD;
&#xD;
               -  Male sterilization (at least 6 months prior to screening). For female subjects on&#xD;
                  the study, the vasectomized male partner should be the sole partner for that&#xD;
                  subject&#xD;
&#xD;
               -  Combination of any of the two following (a+b or a+c or b+c)&#xD;
&#xD;
                    -  a. Use of oral, injected or implanted hormonal methods of contraception or&#xD;
                       other forms of hormonal contraception that have comparable efficacy (failure&#xD;
                       rate &lt;1%), for example hormone vaginal ring or transdermal hormone&#xD;
                       contraception.&#xD;
&#xD;
                    -  b. Placement of an intrauterine device (IUD) or intrauterine system (IUS).&#xD;
&#xD;
                    -  c. Barrier methods of contraception: Condom or Occlusive cap (diaphragm or&#xD;
                       cervical/vault caps) with spermicidal foam/gel/film/cream/vaginal&#xD;
                       suppository.&#xD;
&#xD;
               -  In case of use of oral contraception, women should have been stable on the same&#xD;
                  pill before taking study treatment.&#xD;
&#xD;
               -  Note: Oral contraceptives are allowed but should be used in conjunction with a&#xD;
                  barrier method of contraception due to unknown effect of drug-drug interaction.&#xD;
                  Women are considered post-menopausal and not of child-bearing potential if they&#xD;
                  have had 12 months of natural (spontaneous) amenorrhea with an appropriate&#xD;
                  clinical profile (e.g. age appropriate, history of vasomotor symptoms) or have&#xD;
                  had surgical bilateral oophorectomy (with or without hysterectomy) or tubal&#xD;
                  ligation at least six weeks ago. In the case of oophorectomy alone, only when the&#xD;
                  reproductive status of the woman has been confirmed by follow up hormone level&#xD;
                  assessment is she considered not of child-bearing potential&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with a known allergy, hypersensitivity, or contraindication to the protocol&#xD;
             therapies or any of their components to be used in the arm the subject is to be&#xD;
             enrolled on&#xD;
&#xD;
          -  Uncontrolled or significant cardiovascular disease, including any of the following:&#xD;
&#xD;
               -  Bradycardia of less than 50 beats per minute, unless the subject has a pacemaker;&#xD;
&#xD;
               -  Corrected QT interval Fridericia's Correction Formula (QTcF) interval &gt; 450 msec;&#xD;
&#xD;
               -  Diagnosis of or suspicion of long QT syndrome (including family history of long&#xD;
                  QT syndrome);&#xD;
&#xD;
               -  Systolic blood pressure &gt;=180 mmHg or diastolic blood pressure &gt;=110 mmHg;&#xD;
&#xD;
               -  History of clinically relevant ventricular arrhythmias within 6 months prior to&#xD;
                  screening (eg, ventricular tachycardia, ventricular fibrillation, or Torsade de&#xD;
                  Pointes);&#xD;
&#xD;
               -  History of second (Mobitz II) or third-degree heart block (subjects with&#xD;
                  pacemakers are eligible if they have no history of fainting or clinically&#xD;
                  relevant arrhythmias while using the pacemaker);&#xD;
&#xD;
               -  History of uncontrolled angina pectoris, unstable angina or myocardial&#xD;
                  infarction, coronary artery bypass graft (CABG), cerebrovascular accident (CVA),&#xD;
                  transient ischemia attack (TIA), symptomatic pulmonary emboli within 6 months&#xD;
                  prior to screening;&#xD;
&#xD;
               -  New York Heart Association Class 3 or 4 heart failure;&#xD;
&#xD;
               -  Left ventricular ejection fraction (LVEF) =&lt; 50 or less than the institutional&#xD;
                  lower limit of normal;&#xD;
&#xD;
               -  Complete left bundle branch block (right bundle branch block is permitted, but&#xD;
                  requires manual reading of the QTc interval);&#xD;
&#xD;
               -  Active cardiac dysrhythmias of National Cancer Institute (NCI) Common Terminology&#xD;
                  Criteria for Adverse Events (CTCAE) grade &gt;= 2 (eg, atrial fibrillation)&#xD;
&#xD;
          -  Persisting toxicity related to prior therapy of grade &gt; 1 NCI-CTCAE v 5.0; however,&#xD;
             alopecia and sensory neuropathy grade 2 or lower is acceptable&#xD;
&#xD;
          -  Underwent HSCT within 90 days of the first dose of protocol therapy, or subjects with&#xD;
             clinically significant (grade 2 or greater) graft-versus-host disease (GVHD) (the use&#xD;
             of topical steroids for ongoing cutaneous GVHD is permitted)&#xD;
&#xD;
          -  Subjects with symptomatic CNS leukemia or subjects with poorly controlled CNS leukemia&#xD;
&#xD;
          -  Active and uncontrolled disease (active infection requiring systemic therapy, fever&#xD;
             likely secondary to infection within prior 48 hours, uncontrolled hypertension despite&#xD;
             adequate medical therapy as judged by the treating physician)&#xD;
&#xD;
          -  Active (uncontrolled, metastatic) other malignancies&#xD;
&#xD;
          -  Major surgery within 28 days prior to the first dose of protocol therapy&#xD;
&#xD;
          -  Known dysphagia, short-gut syndrome, gastroparesis, or other conditions that limit the&#xD;
             ingestion or gastrointestinal absorption of drugs administered orally&#xD;
&#xD;
          -  Known history of testing positive for human immunodeficiency virus (HIV) or known&#xD;
             acquired immunodeficiency syndrome (test at screening only if required by local&#xD;
             regulations)&#xD;
&#xD;
          -  Known history of hepatitis B virus (HBV) or hepatitis C virus (HCV) infection with&#xD;
             active Hepatitis B or C infection at screening (positive HBV surface antigen or HCV&#xD;
             ribonucleic acid [RNA] if anti-HCV antibody screening test positive)&#xD;
&#xD;
          -  Vaccination within 4 weeks of the first dose of study drug and while on trials is&#xD;
             prohibited except for administration of inactivated vaccines&#xD;
&#xD;
          -  Subjects who are currently receiving treatment with medication that meet one of the&#xD;
             following criteria and that cannot be discontinued at least one week prior to the&#xD;
             start of DS-1594b treatment:&#xD;
&#xD;
               -  Medications that may prolong QTc interval and have a known risk of inducing&#xD;
                  Torsades de Pointes unless it is vital for the care of the subjects&#xD;
&#xD;
               -  Strong inhibitors or inducers of CYP3A&#xD;
&#xD;
               -  CYP3A and CYP2C19 substrates with narrow therapeutic index&#xD;
&#xD;
          -  Subjects who consume grapefruit products, Seville oranges, or star fruit within 3 days&#xD;
             prior to the first DS-1594b administration and until the last day of DS-1594b is&#xD;
             completed&#xD;
&#xD;
          -  SUB-STUDIES: Subjects who are currently receiving moderate inhibitors or inducers of&#xD;
             CYP3A who cannot discontinue at least one week prior to the start of DS-1594b&#xD;
             treatment till the end of sub-study period&#xD;
&#xD;
          -  SUB-STUDIES: Subjects who are currently receiving proton pump inhibitors who cannot&#xD;
             discontinue at least 2 days prior to the start of DS-1594b treatment till the end of&#xD;
             sub-study period&#xD;
&#xD;
          -  Other severe acute or chronic medical conditions that is active and not well&#xD;
             controlled including renal, skeletal muscle, adrenal insufficiency, colitis,&#xD;
             inflammatory bowel disease, or psychiatric conditions including recent (within the&#xD;
             past year) or active suicidal ideation or behavior; or laboratory abnormalities that&#xD;
             may increase the risk associated with study participation or study treatment&#xD;
             administration or may interfere with the interpretation of study results and, in the&#xD;
             judgment of the investigator, would make the subject inappropriate for entry into this&#xD;
             study&#xD;
&#xD;
          -  Subjects unwilling or unable to comply with the protocol, including:&#xD;
&#xD;
               -  Pregnant or breastfeeding women or women of childbearing potential who are unable&#xD;
                  to comply with appropriate contraception as outlined in or who plan to become&#xD;
                  pregnant while in the study or for at least 6-7 months after last administration&#xD;
                  of study treatment&#xD;
&#xD;
               -  Known alcohol or drug abuse within the last 1 year&#xD;
&#xD;
               -  In a man whose sexual partner is a woman of childbearing potential, unwillingness&#xD;
                  or inability to use an acceptable contraceptive method for the entire study&#xD;
                  period and for at least 3 months after study completion&#xD;
&#xD;
          -  Acute promyelocytic leukemia (APL)&#xD;
&#xD;
          -  Uncontrolled or poorly controlled adrenal or pituitary disease (including adrenal&#xD;
             insufficiency, Addison's disease, Cushing's disease)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Naval G Daver</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naval G. Daver</last_name>
      <phone>713-794-4392</phone>
      <email>ndaver@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Naval G. Daver</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>February 3, 2021</study_first_submitted>
  <study_first_submitted_qc>February 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 12, 2021</study_first_posted>
  <last_update_submitted>July 1, 2021</last_update_submitted>
  <last_update_submitted_qc>July 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Acute</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Chronic</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Juvenile</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Voriconazole</mesh_term>
    <mesh_term>Posaconazole</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cortisone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>Venetoclax</mesh_term>
    <mesh_term>Antineoplastic Agents, Immunological</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Mesna</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

